AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $220.81, giving the company a market capitalization of 390.25B. It carries a P/E multiple of 93.32 and pays a dividend yield of 3.0%.
As of 2026-02-11, AbbVie(ABBV) stock has fluctuated between $218.91 and $223.04. The current price stands at $220.81, placing the stock +0.9% above today's low and -1.0% off the high.
The AbbVie(ABBV)'s current trading volume is 534.66K, compared to an average daily volume of 7.82M.
During the past year, AbbVie(ABBV) stock moved between $164.39 at its lowest and $244.81 at its peak.
During the past year, AbbVie(ABBV) stock moved between $164.39 at its lowest and $244.81 at its peak.
ABBV News
Advertisement Why AbbVie’s latest earnings and pipeline moves matter now AbbVie (ABBV) has just paired a strong fourth quarter with two important developments...
Abbvie (ABBV) announced an update on their ongoing clinical study. The AbbVie (ABBV) PHASES study, officially titled “Prodrome in tHe reAl World: aSsESsing Ubr...
In early February 2026, AbbVie reported past fourth-quarter 2025 results showing sales rising to US$16,618 million and net income improving to US$1,816 million,...
Analyst ratings
64%
of 33 ratingsMore ABBV News
AbbVie has submitted regulatory applications to the FDA and EMA for Rinvoq as a potential systemic treatment for non segmental vitiligo. The filings target a c...
Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the March 27th expiration. At Stock Options Channel , our YieldBoost formula...
Abbvie (ABBV) announced an update on their ongoing clinical study. Study Overview AbbVie is running a real-world study in Japan called “A Study to Evaluate Sa...
The S&P 500, Nasdaq 100, and Russell 2000 all traded lower as tech continued to be the worst-performing sector, while materials and energy fared the best. Cryp...
Evercore ISI analyst Gavin Clark-Gartner lowered the firm’s price target on AbbVie (ABBV) to $228 from $232 and keeps an Outperform rating on the shares. Despit...
Clear Street analyst Kaveri Pohlman believes AbbVie’s (ABBV) plan to bring an extended half-life anti-IL-23 mAb into the clinic this year further validates Oruk...
AbbVie Inc. (NYSE:ABBV) reported fourth-quarter 2025 sales of $16.62 billion on Wednesday, beating the consensus of $16.42 billion. Sales increased 10% on a re...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.